Investigation of Genetic Risk of Atrial Fibrillation

The recruitment status of this study is unknown because the information has not been verified recently.

Verified December 2006 by Nagoya University.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Nagoya University

ClinicalTrials.gov Identifier:

NCT00412438

First received: December 15, 2006

Last updated: NA

Last verified: December 2006

History: No changes posted

Purpose

The atrial fibrillation (AF) is the most common cardiac rhythm disturbance that is responsible for substantial morbidity and mortality independent of associated heart disease or other risk factors. Even in the absence of preexisting cardiovascular disease, AF remains significantly associated with excess mortality rates. The current unsatisfactory treatment for AF comes from lack of understanding of the pathophysiology of AF. The purpose of this study is to identify gene polymorphisms that confer susceptibility to atrial fibrillation. Patients with AF（N=500） and healthy volunteer（N=1000） without AF are enrolled in this study. Patients with coronary artery disease, severe valvular heart disease, cardiomyopathy or heart failure were excluded from the study.

Condition
Atrial Fibrillation


Study Type:	Observational
Study Design:	Observational Model: Case Control Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Retrospective
Official Title:	Investigation of Genetic Risk of Atrial Fibrillation

Resource links provided by NLM:

Genetics Home Reference related topics: familial atrial fibrillation

MedlinePlus related topics: Atrial Fibrillation

Genetic and Rare Diseases Information Center resources: Familial Atrial Fibrillation

U.S. FDA Resources

Further study details as provided by Nagoya University:


Estimated Enrollment:	1000
Study Start Date:	October 2006

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Clinical diagnosis of atrial fibirillation

Exclusion Criteria:

coronary artery disease
severe valvular heart disease
cardiomyopathy
heart failure

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00412438

Contacts


Contact: Kenji Yasui, MD, PhD	+81-52-788-6211	kenji@riem.nagoya-u.ac.jp
Contact: Masaki Yamauchi, MD	+81-52-788-6210	g030744d@mbox.nagoya-u.ac.jp

Locations


Japan
Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University	Recruiting
Nagoya, Aichi, Japan
Contact: Kenji Yasui, MD, PhD +81-52-6211 kenji@riem.nagoya-u.ac.jp
Contact: Masaki Yamauchi, MD +81-52-6211 g030744d@mbox.nagoya-u.ac.jp

Sponsors and Collaborators

Nagoya University

Investigators


Study Chair:	Kenji Yasui, MD, Phd	Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University

More Information


ClinicalTrials.gov Identifier:	NCT00412438 History of Changes
Other Study ID Numbers:	RIEM-G-1
Study First Received:	December 15, 2006
Last Updated:	December 15, 2006
Health Authority:	Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Nagoya University:


Atrial Fibrillation

Additional relevant MeSH terms:


Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes

ClinicalTrials.gov processed this record on September 30, 2016

To Top